Seattle Genetics (SGEN) Offers Updated Survival Data for Adcetris Trial, Says Median Overall Survival at 24 Months 65%

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced updated survival data from a pivotal clinical trial of single-agent ADCETRIS (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up. The data will be reported during an oral presentation at the 17th European Hematology Association (EHA) Annual Meeting being held June 14-17, 2012 in Amsterdam, Netherlands. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.

Long-term Follow-up Results of an Ongoing Pivotal Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

A pivotal trial was conducted in 102 patients with relapsed or refractory HL after ASCT. The primary endpoint was objective response rate (ORR) per independent review. The secondary endpoints were complete remission (CR) rate, duration of response, progression-free survival (PFS), overall survival (OS), and safety and tolerability. At the time of the long-term follow-up analysis, the median observation time from first dose was 26.5 months. Data, to be presented by Dr. Smith, include:

• As previously reported, the ORR was 75 percent (76 of 102 patients), with CRs observed in 33 percent of patients (n=34).
  
• The median OS had not been reached at the time of the analysis. The estimated OS at 24 months was 65 percent.
  
• The median PFS for all patients was 5.6 months. The median PFS for patients achieving a CR was 29 months.
  
• As previously reported, the most common (≥20 percent) adverse events (AEs) of any grade were peripheral sensory neuropathy (47 percent), fatigue (46 percent), nausea (42 percent), upper respiratory tract infection (37 percent), diarrhea (36 percent), pyrexia (29 percent), neutropenia (22 percent), vomiting (22 percent) and cough (21 percent).
  
• Of the AEs that were reported in ≥20 percent of patients, Grade 3 or higher events included neutropenia (20 percent), peripheral sensory neuropathy (9 percent), fatigue (2 percent), pyrexia (2 percent) and diarrhea (1 percent).

Patients received 1.8 milligrams per kilogram of ADCETRIS every 3 weeks as a 30-minute outpatient intravenous infusion for up to 16 cycles. Patients received a median of nine cycles of ADCETRIS while on trial. The median age of patients in the pivotal trial was 31 years. Enrolled patients had received a median of 3.5 (range 1–13) prior cancer-related systemic therapies, excluding ASCT. Seventy-one percent of patients had primary refractory disease, defined in the study protocol as patients who relapsed within three months of attaining CR or failed to achieve a CR, and 42 percent had not responded to their most recent prior therapy.

Details of the oral presentation are as follows:

• Sunday, June 17; 8:30 AM – 8:45 AM Central European Summer Time (CEST)
  
• Abstract #1109
  
• Oral presentation in Hall 2
  
• First author: Scott Smith M.D., Ph.D., Loyola University Medical Center

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Nu Skin EVP of global sales takes medical leave
• Hinge Health signs $86M office lease in San Francisco